$SDZNY News

Last published 1y ago

1y agoSDZNYSandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in USBusiness WireExpands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches Strengthens US supply of injectable iron
1y agoSDZNYSandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operationsGlobeNewswireMEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in SpainWill cover nearly 90% of electricity demand for European operationsConcrete step to support global Sandoz
1y agoSDZNYSandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarterGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz ((SIX: SDZ, OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today presents
1y agoSDZNYSandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, FranceGlobeNewswireAd-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar
1y agoSDZNYSandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reachGlobeNewswireMEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 yearsOngoing investment in in-house
1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum: Now Available for Online ViewingGlobeNewswireNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and
1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum Agenda Announced for June 11th-12thGlobeNewswireNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is
1y agoSDZNYSandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]GlobeNewswireAd-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab
1y agoSDZNYSandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilarsGlobeNewswireMEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and quality of
1y agoSDZNYSandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmedGlobeNewswireAd-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a comparable growth rate
1y agoSDZNYSandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indicationsGlobeNewswireMEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to develop
1y agoSDZNYShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGGlobeNewswireAll proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for re-election confirmed Dividend of CHF 0.60 per registered
1y agoSDZNY[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the USGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to "Important Safety Information" updated Company aims to accelerate
1y agoSDZNYSandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the USGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory
1y agoSDZNYSandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facilityGlobeNewswireMEDIA RELEASENOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and
1y agoSDZNYSandoz signs landmark supply and manufacturing agreementGlobeNewswireSandoz signs 10-year agreement with partner Delpharm, a global pharmaceutical developer and contract manufacturerAgreement will secure a reliable supply of affordable, quality sterile injectables made in CanadaWith this
1y agoSDZNYSandoz reports strong FY 2024 results and Q4 2024 salesGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2.7 billion, up by
1y agoSDZNYSandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]GlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens
1y agoSDZNYFrancisco Ballester to retire; Peter Stenico appointed President Region InternationalGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of servicePeter Stenico, currently Global
1y agoSDZNYSandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market Europe, which
1y agoSDZNYSandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolioGlobeNewswireMEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains
2y agoSDZNYSandoz reports third-quarter and nine-month 2024 salesGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics
2y agoSDZNYSandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolioGlobeNewswireMEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be near-term growth
2y agoSDZNYIntroducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian marketGlobeNewswire— Jubbonti® and Wyost® are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access for patients — Jubbonti® and Wyost® approved for all indications of
2y agoSDZNYSandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar positionGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degenerationFurther enhances leading US ophthalmology
2y agoSDZNYSandoz reports second-quarter sales and half-year 2024 resultsGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net
2y agoSDZNYSandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseasesGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting
2y agoSDZNYFDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in USGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved
2y agoSDZNYImproving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolioGlobeNewswirePrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge
2y agoSDZNYSandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in EuropeGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of
2y agoSDZNYSandoz reports first quarter 2024 salesGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in
2y agoSDZNYShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGGlobeNewswireAll proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly and Michael
2y agoSDZNYSandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for
2y agoSDZNYSandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming match to
2y agoSDZNYSandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesGlobeNewswireMEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in EuropeAdditional manufacturing area of 3,000m2 means Kundl can now
2y agoSDZNYSandoz reports fourth quarter 2023 sales and full-year 2023 resultsGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD)Full-year
2y agoSDZNYSandoz receives FDA approval for first and only denosumab biosimilarsGlobeNewswireMEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*
2y agoSDZNYSandoz announces nominations to the Board of Directors and leadership changeGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General
2y agoSDZNYSandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US marketGlobeNewswireMEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team
2y agoSDZNYSandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosisGlobeNewswireBiosimilar Jubbonti® approved for all indications of Prolia* reference medicine.Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone
2y agoSDZNYSandoz announces changes in the Board of DirectorsGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General
2y agoSDZNYSandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in GermanyGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults
2y agoSDZNYSandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US marketGlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**
2y agoSDZNYSandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient careGlobeNewswireBiosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across
3y agoSDZNYSandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in GermanyGlobeNewswireInvestment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicinesNew penicillin production process will significantly improve ecological footprint and help secure European-based
3y agoSDZNYSandoz successfully issues EUR 2.0 billion inaugural EurobondsGlobeNewswireNOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 millionMaturities of 3.5, 6.5 and
3y agoSDZNYSandoz successfully issues CHF 750 million in inaugural bondsGlobeNewswireHighly successful inaugural CHF senior bonds priced earlier todayTwo tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons, respectivelyProceeds to
3y agoSDZNYSandoz reports year-to-date sales for the first nine months of 2023GlobeNewswireAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1)Solid performance in Generics; Biosimilars grow
3y agoNVS OTCM SDZNYOTC Markets Group Welcomes Sandoz Group AG to OTCQXGlobeNewswireNEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Sandoz Group AG ((SIX Swiss Exchange:
3y agoSDZNYSandoz enters new era as standalone global leader and European champion in generic and biosimilar medicinesGlobeNewswireSpin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indicesStandalone Sandoz committed to extend leadership in stable and growing market